Objective: Germ cell tumors are the tumors sensitive for adjuvant therapy such as radiotherapy and chemotherapy. We evaluated the pathological findings of these heterogeneous tumors to determine the persistence of residual viable tumor cells after adjuvant therapy. Patients and Methods: Between 1988 and 2005, we treated 31 patients with germinoma or germinoma with syncytiotrophoblastic giant cells (STGC) and 15 patients with non-germinomatous malignant germ cell tumors (NGMGCTs). All 46 patients received a combination of chemo- and radiotherapy. A second-look operation was performed in 3 of 31 patients with germinomas or germinomas with STGC and 12 of 15 patients with NGMGCTs. The follow-up period was 2–139 months (median 95) in patients with germinomas or germinomas with STGC (group 1) and 10–202 months (median 65) in NGMGCT patients (group 2). Results: Post-treatment, 3 group 1 and 12 group 2 patients manifested residual tumors. The pathological diagnosis in group 1 patients was mature teratoma, pineal cyst, and fibrous tissue with calcification; in group 2 it was yolk sac tumor (n = 1), immature teratoma (n = 3), mature teratoma (n = 4), and necrosis or fibrous tissue (n = 4). While no group 1 patients manifested tumor cells, MIB-1-positive viable tumor cells were present in resected tissues from one-third of the group 2 patients (3 immature teratomas and 1 yolk sac tumor). Conclusion: The absence of viable tumor cells in residual tissue indicates that the combination of cisplatin-based chemo- and radiotherapy was effective in our germinoma patients. On the other hand, in patients with NGMGCTs, these cells persisted despite this combination therapy.

Keywords:
Adjuvant therapy, Adjuvant therapy, residual tissue evaluation, Germ cell tumors, Germinomas, Non-germinomatous malignant germ cell tumors, Pediatric CNS tumors, Residual tissues, evaluation, Syncytiotrophoblastic giant cells
1.
Kuratsu J, Ushio Y: Epidemiological study of primary intracranial tumors in childhood. A population-based survey in Kumamoto Prefecture, Japan. Pediatr Neurosurg 1996;25:240–246.
2.
Kuratsu J, Ushio Y: Epidemiological study of primary intracranial tumors: a regional survey in Kumamoto Prefecture in the southern part of Japan. J Neurosurg 1996;84:946–950.
3.
Hardenbergh PH, Golden J, Billet A, Scott RM, Shrieve DC, Silver B, Loeffler JS, Tarbell NJ: Intracranial germinoma: the case for lower dose radiation therapy. Int J Radiat Oncol Biol Phys 1997;39:419–426.
4.
Shibamoto Y, Sasai K, Oya N, Hiraoka M: Intracranial germinoma: radiation therapy with tumor volume-based dose selection. Radiology 2001;218:452–456.
5.
Baranzelli MC, Patte C, Bouffet E, Couanet D, Habrand JL, Portas M, Lejars O, Lutz P, Le Gall E, Kalifa C: Nonmetastatic intracranial germinoma: the experience of the French Society of Pediatric Oncology. Cancer 1997;80:1792–1797.
6.
Buckner JC, Peethambaram PP, Smithson WA, Groover RV, Schomberg PJ, Kimmel DW, Raffel C, O’Fallon JR, Neglia J, Shaw EG: Phase II trial of primary chemotherapy followed by reduced-dose radiation for CNS germ cell tumors. J Clin Oncol 1999;17:933–940.
7.
Sawamura Y, Ikeda J, Shirato H, Tada M, Abe H: Germ cell tumours of the central nervous system: treatment consideration based on 111 cases and their long-term clinical outcomes. Eur J Cancer 1998;34:104–110.
8.
Robertson PL, DaRosso RC, Allen JC: Improved prognosis of intracranial non-germinoma germ cell tumors with multimodality therapy. J Neurooncol 1997;32:71–80.
9.
Jennings MT, Gelman R, Hochberg F: Intracranial germ-cell tumors: natural history and pathogenesis. J Neurosurg 1985;63:155–167.
10.
Matsutani M, Sano K, Takakura K, Fujimaki T, Nakamura O: Combined treatment with chemotherapy and radiation therapy for intracranial germ cell tumors. Childs Nerv Syst 1996;14:59–62.
11.
Matsutani M: Combined chemotherapy and radiation therapy for CNS germ cell tu mors – the Japanese experience. J Neurooncol 2001;54:311–316.
12.
Ushio Y, Kochi M, Kuratsu J, Itoyama Y, Marubayashi T: Preliminary observations for a new treatment in children with primary intracranial yolk sac tumor or embryonal carcinoma. Report of five cases. J Neurosurg 1999;90:133–137.
13.
Kochi M, Itoyama Y, Shiraishi S, Kitamura I, Marubayashi T, Ushio Y: Successful treatment of intracranial nongerminomatous malignant germ cell tumors by administering neoadjuvant chemotherapy and radiotherapy before excision of residual tumors. J Neurosurg 2003;99:106–114.
14.
Muller AM, Ihorst G, Waller CF, Dolken G, Finke J, Engelhardt M: Intensive chemotherapy with autologous peripheral blood stem cell transplantation during a 10-year period in 64 patients with germ cell tumor. Biol Blood Marrow Transplant 2006;12:355–365.
15.
Robison LL, Nesbit ME Jr, Sather HN, Level C, Shahidi N, Kennedy A, Hammond D: Down syndrome and acute leukemia in children: a 10-year retrospective survey from Children’s Cancer Study Group. J Pediatr 1984;105:235–242.
16.
Chessells JM, Harrison G, Richards SM, Bailey CC, Hill FG, Gibson BE, Hann IM: Down’s syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment. Arch Dis Child 2001;85:321–325.
17.
Satge D, Monteil P, Sasco AJ, Vital A, Ohgaki H, Geneix A, Malet P, Vekemans M, Rethore MO: Aspects of intracranial and spinal tumors in patients with Down syndrome and report of a rapidly progressing Grade 2 astrocytoma. Cancer 2001;91:1458–1466.
18.
Dieckmann KP, Rube C, Henke RP: Association of Down’s syndrome and testicular cancer. J Urol 1997;157:1701–1704.
19.
Satge D, Sasco AJ, Chompret A, Orbach D, Mechinaud F, Lacour B, Roullet B, Martelli H, Bergeron C, Bertrand Y, Lacombe D, Perel Y, Monteil P, Nelken B, Bertozzi AI, Munzer M, Kanold J, Bernard F, Vekemans MJ, Sommelet D: A 22-year French experience with solid tumors in children with Down syndrome. Pediatr Hematol Oncol 2003;20:517–529.
20.
Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A: Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987;6:3341–3351.
21.
Shearman MS, Herbst R, Schlessinger J, Ullrich A: Phosphatidylinositol 3′-kinase associates with p145c-kit as part of a cell type characteristic multimeric signalling complex. EMBO J 1993;12:3817–3826.
22.
Miyanohara O, Takeshima H, Kaji M, Hirano H, Sawamura Y, Kochi M, Kuratsu J: Diagnostic significance of soluble c-kit in the cerebrospinal fluid of patients with germ cell tumors. J Neurosurg 2002;97:177–183.
23.
Takeshima H, Kuratsu J: A review of soluble c-kit (s-kit) as a novel tumor marker and possible molecular target for the treatment of CNS germinoma. Surg Neurol 2003;60:321–324.
24.
Nakamura H, Takeshima H, Makino K, Kuratsu J: c-kit expression in germinoma: an immunohistochemistry-based study. J Neurooncol 2005;75:163–167.
25.
De Santis M, Pont J: The role of positron emission tomography in germ cell cancer. World J Urol 2004;22:41–46.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.